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A B S T R A C T
Background
Mitochondrial DNA (mtDNA) is being analyzed by an increasing number of laboratories in
order to investigate its potential role as an active marker of tumorigenesis in various types of
cancer. Here we question the conclusions drawn in most of these investigations, especially
those published in high-rank cancer research journals, under the evidence that a significant
number of these medical mtDNA studies are based on obviously flawed sequencing results.
Methods and Findings
In our analyses, we take a phylogenetic approach and employ thorough database searches,
which together have proven successful for detecting erroneous sequences in the fields of
human population genetics and forensics. Apart from conceptual problems concerning the
interpretation of mtDNA variation in tumorigenesis, in most cases, blocks of seemingly somatic
mutations clearly point to contamination or sample mix-up and, therefore, have nothing to do
with tumorigenesis.
Conclusion
The role of mitochondria in tumorigenesis remains unclarified. Our findings of laboratory
errors in many contributions would represent only the tip of the iceberg since most published
studies do not provide the raw sequence data for inspection, thus hindering a posteriori
evaluation of the results. There is no precedent for such a concatenation of errors and
misconceptions affecting a whole subfield of medical research.
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Introduction
For more than two decades human mitochondrial DNA
(mtDNA) has widely been used as a versatile tool to
investigate different genetic aspects such as the origin and
migration patterns of human populations or criminal case-
work in the forensic ﬁeld. Speciﬁc mutations in the mtDNA
genome are also suggested to be responsible for human
diseases such as Leber hereditary optic neuropathy, myo-
clonic epilepsy associated with ragged-red ﬁber disease,
MELAS syndrome, deafness, and inherited adult-onset dia-
betes (see [1] for a recent review). In the past few years, the
putative role of mtDNA in cancer has received special
attention. While many studies seem to support an active role
of mtDNA in tumorigenesis [2,3], there are many caveats, and
the issue has been highly debated [4–6].
Owing to the multiple steps involved in mtDNA analysis,
systematic errors in mtDNA sequences are often found in the
anthropological and forensic literature [7–11]. Thus one
should also expect to detect similar problems in clinical
investigations. More than half of published mtDNA sequenc-
ing studies contain obvious errors, no matter in which journal
the investigation is published [12]. The consequences of such
errors can be more or less dramatic depending on the subject
or particular case under study. In the forensic context, a
single mistake can lead to the false exclusion of an individual
as the source of the biological material left at a crime scene or
to a mismatch in comparisons of an mtDNA proﬁle with
forensic databases. Systematic errors can also lead to bio-
logical dogmas such as the maternal inheritance of mtDNA
being brought into question [13]. In an oncogenetic context,
ﬂawed sequence data can lead to a conclusion of false
association between seemingly causal variants and tumor
instability.
A phylogenetic approach to the analysis of mtDNA proﬁles
(in which the sequences under consideration are compared
with the current database of complete sequences that make
up the global mtDNA phylogeny) has been shown to be useful
for assessing the accuracy of mtDNA data [14]. In the clinical
context, such an approach allows mtDNA sequences to be
assigned to haplogroups alias monophyletic clades (that is,
groups of all mtDNA sequences derived from a common
ancestor), according to the haplogroup-speciﬁc mutations
they harbor, and offers clues for pinpointing ﬂaws. The
mutational processes that lead to a cancer (or the mutations
accumulating during cancer proliferation) could hardly
reproduce by chance (mutation by mutation) the long
evolutionary routes between distant mtDNA haplogroups.
Therefore, when a tumor sample is apparently distinguished
from the corresponding normal tissue sample by (nearly) all
the mutations distinguishing two very different haplogroups,
then the only conclusion is that one of the two samples was
contaminated or exchanged by mistake.
Methods
MtDNA Databases for the Interpretation of Human
Population Variation
The use of large worldwide databases is of great help for
identifying matching sequences and conﬁrming membership
to speciﬁc haplogroups, as well as for obtaining information
about their geographical distribution (phylogeography). In
order to study mtDNA variation properly it is necessary to
take the full body of published mtDNA studies into
consideration. While MITOMAP (http://www.mitomap.org/)
provides a useful (but incomplete) listing of single mutations
that have appeared in the older medical literature, direct
reference to population databases of complete or nearly
complete mtDNA sequences allows the inference of muta-
tions that have occurred on evolutionary pathways between
reconstructed ancestral sequences. Thus, a snapshot of the
global mtDNA phylogeny and some of its representatives in
all continents is given by the complete sequences of Ingman
et al. [15], although the accompanying diagrams are devoid of
the information that a medical geneticist would need, namely,
a reconstruction of the coding-region mutations along the
estimated phylogeny. The data of Herrnstadt et al. [16,17],
which comprise only the coding region, give additional
information, with the emphasis on European mtDNA, while
Kong et al. [18] data contain East Asian complete genomes.
Coble et al. [19] provided a considerable number of new
complete mtDNA genomes, which were preselected accord-
ing to frequent control-region haplotypes found in Europe.
Most recently, Palanichamy et al. [20] obtained 75 complete
sequences from haplogroup N sampled in India, and Achilli
et al. [21] published 62 complete mtDNAs, covering most of
the basal variation of haplogroup H.
The deeper parts of the global mtDNA phylogeny are
expressed through a system of nested haplogroups, which are
encoded by strings of letters and numbers in alternation,
following speciﬁc rules [22]. In what follows we make use of
this haplogroup nomenclature [18,20] in order to reference
the pertinent sections of the phylogeny.
Results
The Unsuitability of an ‘‘Allelic’’ Approach
Uniparental markers, such as mtDNA, were newcomers to
the ﬁeld of human genetics, where classical nuclear markers
had been predominant. Consequently, the analysis of the new
markers proceeded in the traditional way by treating the
segregating nucleotides at each polymorphic position in the
sequence as alleles and treating each position independently
so that haplotypes were disrupted, and the strong association
of certain mutations along the phylogeny was disregarded
completely. The cumulative listing of mtDNA mutations
observed in patients or controls [23,24] is therefore not only
rather uninformative but often misleading.
The strategy followed by Nishikawa et al. [25] will serve as a
paradigmatic example of what is conceptually inappropriate.
These authors sequenced the entire mtDNA genome of two
individuals with hepatocellular carcinoma (HCC) and a liver
specimen from one control, as well as the D-loop region (only
nucleotides 100–600) of another six controls and 69 HCC
specimens of Japanese subjects. They used an arbitrary
mtDNA complete genome deposited in GenBank (accession
number J01415) as a reference sequence. This sequence
differs from the revised Cambridge reference sequence (rCRS
[26]) by four mutations: A4985G, C11335T, C14766T (con-
stituting three of the 11 errors of the original Cambridge
reference sequence [27]), and A750G; it is actually an artiﬁcial
sequence phylogenetically related to haplogroup H. When
comparing the mtDNA of the control liver specimen with the
J01415 sequence, they found only three differences. Judging
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from the context in their paper, the three differences,
however, must be A263G, 315þC, and T489C. Thus, all
sequences were erroneously scored at the four positions
750, 4985, 11335, and 14766. The presence of the substitution
T489C indicates that the control lineage belongs to one of the
haplogroups M and J, very likely to the former because
haplogroup J is virtually absent in Japanese, but this is at odds
with the meager number of differences to the rCRS. Even
more alarmingly, since all samples screened for region 100–
600 were claimed to harbor those three mutations in the D-
loop, we would then expect no single sequence from
haplogroup N (which embraces the East Eurasian hap-
logroups A, B, F, etc.) in 78 individuals. This is very unlikely
when we consider the haplogroup distribution pattern in
large Japanese mtDNA datasets [28], which testify to more
than 30% of haplogroup N sequences. It therefore seems that
contamination with some haplogroup M sequence had
affected the samples. Finally, the authors compared the
mtDNAs of two cancerous tissue specimens with sequence
J01415 and found as many as 67 and 77 mutations,
respectively (half of them also present in the paired non-
cancerous tissue specimens of the two patients). The two
cancerous tissues seem to share several mutations, especially
in the region 11000–16000 of the mtDNA genome rather than
with their matched noncancerous tissues (see their Figure 1),
which again would make contamination or sample mix-up
plausible as a cause for the incidence of seemingly somatic
mtDNA mutations in HCCs. There is no consistent way to
allocate the mutations that separate the rCRS from the root
of haplogroup H (or R) or the mutations distinguishing M and
R in their Figure 1 (see [25]). It seems that massive oversight
of mutations on the one hand, and contamination on the
other, have shaped the picture presented. Since the total data
obtained by the authors are not reported mutation by
mutation, the likely causes of the sequencing dilemma cannot
be reconstructed more precisely.
Yeh et al. [29] studied mtDNA in papillary thyroid
carcinomas (PTCs). A whole paragraph of the discussion is
dedicated to two (C7521A, A10398G) of the three missense
mutations found in PTC cases. The authors failed to
recognize that both C7521A and A10398G are familiar
mutations in the mtDNA phylogeny. The latter is shared by
nearly all haplotypes outside haplogroup N, whereas the
former is common to virtually all members of the major
African haplogroups L0, L1, and L2. It then seems that the
authors’ statement that ‘‘the 10398A.G and 7521G.A
variants might not be totally innocuous. . .’’ (p. 2064) and
that ‘‘one might speculate that these somatic mtDNA
mutations are low penetrance modiﬁers of tumour risk. . .’’(p.
2064) is most implausible, given the ubiquity of this muta-
tional pair on the African continent. It is also remarkable that
a meager number of 30 controls and nine fetal tissues without
heteroplasmy at positions 7521 and 10398 led the authors to
speculate that ‘‘this suggests that when these mutations are
somatic, they are speciﬁc to PTCs (p. 2064).’’ As we shall see
below, seemingly heteroplasmic or somatic mutations may
be the result of contamination or sample mix-up and
therefore would necessitate more sequencing and cloning
efforts.
Yeh et al. [29] also followed a paradigm that is nearly
ubiquitous in all those studies about the role of mtDNA and
tumorigenesis, namely, the straightforward comparison of a
patient group with an arbitrary control group, by counting
mutations relative to the rCRS. A seemingly larger number of
mutations in the patient group would normally reﬂect
sampling effects in that different parts of the phylogeny are
covered by the mtDNAs of patients compared to controls. In
other words, controls and cases do not necessarily represent
the same population and ethnic matching; this provokes a
well-known effect in popular association studies that leads to
spurious association between probands and the polymor-
phism/mutation under study. For example, only one
(G15179A) out of 16 mutations that were found in PTC but
not in controls and fetal tissues [29] is apparently a mutation
not yet reported in normal mtDNA genomes from worldwide
studies of the past 5 y. Worse, at least three PTC mtDNAs
contribute more than one mutation to the list, which are
inherited from the particular basal branch of the worldwide
phylogeny the mtDNA belongs to. One haplogroup L1b
lineage is responsible for mutations T710C and T3308C that
are characteristic of this haplogroup as well as mutation
T7389C speciﬁc to the superhaplogroup L1. Similarly,
potential Native American mtDNAs from haplogroups D1
and B2 could have contributed two mutations each. The
phylogenetic linkage of mutations therefore violates the tacit
assumption of independence behind any claims of ‘‘signiﬁ-
cance.’’
The most recent claim that one ‘‘can now add cancer to the
list of mitochondrial diseases’’ (see [30], p. 724) in that
mtDNA mutations are associated with a predisposition to
prostate cancer should also be received with skepticism. The
fact that a known pathogenic mutation such as T8993G can
inﬂuence the rate of tumor growth cannot alone corroborate
this claim—nor can a simple correlation study that contrasts
cytochrome oxidase subunit I polymorphisms found in
patients with those found in controls. For instance, mutation
T6253C that is believed to be associated with prostate cancer
[30] belongs to the characteristic mutations for the European
haplogroup H15 [21] and both East Asian haplogroups D5
[18] and M13 [31]. To our knowledge it has not been reported
yet that, in Japan where D5 and M13 thrive, a considerable
number of men suffered from rapidly growing prostate
cancer.
Alleged Mutational Hotspots
Methodological procedures can be prone to sequence
artifacts that can erroneously be interpreted as mtDNA
mutational hotspots. Because of their nature, mutational
hotspots emerge frequently in the mtDNA phylogeny and for
this reason are well known in human population studies. A
familiar example within the clinical literature is the unstable
homopolymeric ‘‘C’’ track in the hypervariable segment II
(HVS-II) region, from positions 303 to 309, but also positions
146, 150, and 152 [6] in the same segment. Turning it the
other way around, rare or stable diagnostic variants are
extremely unlikely to be mutational hotspots.
We highlight the unusual ﬁndings in Khrapko et al. [32] in
this regard. After analyzing a short coding-region fragment of
100 bp by mutational spectrometry, these authors reached
the conclusion that different human tissues and cells
contained a remarkably similar set of hotspot point muta-
tions. However, we observe that the hotspots they reported
are correlated very poorly with the mutational spectra
inferred from human populations. For instance, their two
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most important outstanding ‘‘hotspots’’ (positions 10068 and
10098 in their Figure 3) have never been detected in complete
genome sequencing analysis (despite there being more than
1,700 complete mtDNA genomes available in the literature,
covering most of the basal worldwide mtDNA phylogeny). To
our knowledge, the remaining so-called hotspots have never
been found in the human population literature either, with
the exception of position 10084, which is associated with J1,
K, and L1c lineages [16]. The real causes of this unexpected
result remain obscure, since their methodology used to detect
sequence variants (mutational spectrometry) is seldom used
in the ﬁeld, so one cannot exclude the possibility that it is
strongly affected by artifacts.
The study by Reddy et al. [33] of patients with myelodys-
plastic syndromes also suggested the presence of novel
mutational hotspots. Among them, positions 7264, 7594,
and 7595 have never been detected in population studies,
whereas others such as 7289 have been found in only a single
sequence (Homo sapiens isolate T1–12 mitochondrion, com-
plete genome [19]). Also unrealistic is the fact that 25 out of
52 mutational events listed in their Table III are trans-
versions, whereas another 18 ‘‘instabilities’’ are indels; but
only nine transitions (by far the most common type of change
in mtDNA) were reported (one of these transitions [A7768G]
is diagnostic for haplogroup U5b [20]). The transition:trans-
version ratio for their data contrasts signiﬁcantly with very
conservative estimates taken from hundreds of human
population studies; additionally the extremely high preva-
lence of indels is certainly unrealistic. For similar and
additional reasons, this study has been questioned by others
[5]. Unexpected results must be corroborated with standard
methodology and by independent studies; in this sense, the
commitment of Reddy et al. [33] has not been published yet.
In addition, we agree with Gattermann et al. [5] in that the
detection of mutations within primer annealing sites is at
least unorthodox. The explanations of Reddy et al. [33] are
certainly not convincing and, of course, do not explain the
most striking fact: why have these hotspots not been detected
(even as private variants) anywhere else in population studies?
Contamination and Sample Mix-Up
The recent work of Bandelt et al. [10] analyzed the causes
and consequences of artiﬁcial recombinants, focusing atten-
tion on the forensic and population genetic literature. As
predicted, mtDNA analysis in clinics does not escape the
problem of contamination and sample mix-up. All the studies
that we comment on below have a common denominator:
contamination or sample mix-up of the tumor samples under
study with exogenous mtDNAs. Typically, these ﬁndings
usually lead to innocent erroneous interpretations and the
concomitant development of a biological explanation or the
invocation of a theory that would justify the role of such
variants in tumorigenesis. A classical case constitutes the
ﬁnding of three ‘‘somatic’’ homoplasmic mutations (T710C,
T1738C, and T3308C) in colorectal tumor V478 [2]: these
rather rare mutations all belong to the sequence motif for
haplogroup L1b (see also [34]).
Fliss et al. [3] provide us with a pertinent example in the
analysis of mtDNA sequences in tumor studies. Patient 884
(their Table 1; bladder cancer) shows a total of ﬁve mutations
(T10071C, T10321C, A10792G, C10793T, and C12049T) all of
which have been found in a haplogroup L1c2 lineage, namely,
no. 173 in Herrnstadt et al. [16], which is related to the
African lineage no. 48 in Ingman et al. [15]. Therefore, these
mutations are extremely unlikely to have anything to do with
tumorigenesis but rather represent an instance of contami-
nation or sample mix-up involving a speciﬁc L1c2 mtDNA
(Figure 1). Corroborating evidence comes from their Supple-
mental Table 1 (www.sciencemag.org/feature/data/
1048413.shl), which lists the so-called new mtDNA poly-
morphisms detected at the time as being shared by matched
cancerous and normal tissues. As many as 13 mutations
recorded for the bladder cancer cases are also seen in lineage
no. 173 of Herrnstadt et al. [16], including its seemingly
private mutations A633G, A723G, T5580C, and T15672C. Not
surprisingly, the ﬁve somatic mutations claimed to be somatic
in Patient 884 were missed as polymorphisms in the bladder
cancer patients. This strongly suggests that two amplicons of
normal tissue from Patient 884 (one covering 10071–10793
and the other including 12049) were exchanged with (or
contaminated by) tissues stemming from some other patient
or patients.
The polymorphisms listed in Supplemental Table 1 of Fliss
et al. [3] testify to further problems. Among the mutations
that were found in lung cancer patients, four mutations point
to haplogroup L1c and three additional ones (A2308G,
C11257T, and T11899C) to a very speciﬁc branch of
subhaplogroup L1c1a [15,35]. This being the case, the three
mutations G2758A, C8655T, and A9072G from the evolu-
tionary path between rCRS and haplogroup L1c should have
been recorded there as well—but they were not. Neither had
G2758A been reported for bladder cancer, although L1c was
present there as well. The presence of another mtDNA
haplogroup of African ancestry is documented in that table
of polymorphisms, namely, the six mutations T1738C,
A2768G, T3308C, A8248G, T12519C, and A14769G belong
to the characteristic motif of haplogroup L1b. Five of them
are associated with lung cancer, four with bladder cancer, and
three with head and neck cancer patients. This means that a
total of 1 þ 2 þ 3 ¼ 6 mutations must have been missed in
individual patients (as well as C8655T in the head and neck
cancer case) since natural back mutations in such great
number would be unrealistic. We conclude that sample
contamination or massive oversight of mutations must have
been the rule rather than the exception in Fliss et al. [3].
Jero´nimo et al. [36] claim to have demonstrated the
existence of speciﬁc patterns of somatic mtDNA mutations
in prostate cancer. These authors also reported a spectacular
case in the clinical literature: 18 somatic mutations detected
in one patient (see their Table 1, patient 1). Surprisingly,
many of these alterations conform to the familiar western
European mtDNA haplogroup W [20]: A189G, T204C, G207A,
A3505G, C11674T, A11947G, T12414C, and C12705T (Figure
1). In addition, their Table 1 suspiciously contains variants
such as A3480G that identify haplogroup K, as well as
A12308G and G12372A, which are characteristic of the larger
haplogroup U, in which, haplogroup K is nested. Although
A235G is a good candidate for haplogroup A, it too has been
found within haplogroup K (USA.CAU.001306 in the
SWGDAM database [37]), while other mutations such as
T146C, A16183C (erroneously reported as A16183G in
Jero´nimo et al. [36]), and T16189C can be found on many
haplogroup backgrounds (including haplogroup W). Such an
unbelievable departure from random expectation represents
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a good candidate for cross-contamination between at least
two different samples: one from haplogroup W and one from
K. Therefore, there is no need to invoke the effect of
endogenous factors or catastrophic mutagenic effects of
exogenous exposure for this ‘‘hypermutated individual’’:
‘‘Intriguingly, this patient worked for many years at a
chemical plant’’ (see [36], p. 5196).
Similarly, Kirches et al. [38] carried out pairwise compar-
isons between glioma samples and adjacent brain tissues of 55
patients. Strikingly, patient 2 (their Table 1, p. 536)
Figure 1. Portion of the Worldwide mtDNA Phylogeny That Explains the Most Relevant Contamination/Sample Mix-Up Episodes Erroneously
Interpreted as mtDNA Instabilities in Several Kinds of Tumors or Detected as Germline Mutations, as Commented in the Text
Capital letter-number codes designate haplogroups; bold bars indicate intermediate branching points as inferred from the total mtDNA phylogeny.
Variation at position 16519, length polymorphisms of long C-stretches in HVS-I and II, and dinucleotide repeats at 522–523 are disregarded. All
mutations are transitions except for those suffixed by A, G, C, or T (transversion) or del (deletion) orþ (insertion of the specified nucleotide). Parallel
mutations are underlined. Somatic (red squares) and germline (pink circles) mutations are indicated on the left side of each position in the tree as they
appear in their original studies.
DOI: 10.1371/journal.pmed.0020296.g001
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accumulated a total of 17 homoplasmic transitions, in
contrast with the rest of the instabilities reported, which
are all length variations of (di-)nucleotide repeats in the
control region, except for one homoplasmic change between
glioblastoma and normal tissue (namely, at position 72). The
somatic mutations reported for patient 2 split into two
mutational motifs with respect to rCRS: T195C, T4646C,
T5999C, A6047G, A12937G, T13124C, C14620T, C16134T,
A16293G, T16356C, and T16519C in the glioblastoma and
G185A, T204C, C295T, A5198G, T16126C, and T14798C in
the normal tissue (Figure 1). Here we assume that Kirches et
al. [38] have misrecorded A12937G as A12936G and misas-
signed A5198G to the glioblastoma or interchanged the
nucleotides A and G at 5198 by mistake. Our interpretation
thus posits that 11 of the 13 gliostoma mutations conﬁrm to
the motif of a particular branch of haplogroup U4a [6,17,39],
thus leaving only A16293G and T13124C as potential private
mutations. All six normal tissue mutations point to the (yet
unnamed) branch of haplogroup J1c deﬁned by A5198G
(compare with Coble et al. [19] and Herrnstadt et al. [16,17];
see Figure 1). Although the authors identify most of these
substitutions as known polymorphisms in humans, they failed
to recognize the most plausible justiﬁcation for these results,
namely, contamination or sample mix-up: ‘‘Whatever the
mechanisms of mutation may be, the fast selection of certain
tumor mitochondria, as demonstrated by Polyak et al. (1998),
offers the only simple explanation for the accumulation of 17
homoplasmic mutations in a single tumor sample. . .’’ ([38], p.
537]). As usual, unfortunate results lead to the formulation of
unjustiﬁable conclusions: ‘‘The occurrence of mutations in
tumors at known polymorphic mtDNA sites and the
dominance of transitions suggest a common mechanism
generating germline mtDNA polymorphisms and somatic
mutations’’ ([38], p. 536).
Wong et al. ([40], p. 3870) stated that ‘‘Kirches et al. (2001)
reported 19 somatic mtDNA mutations found in a single
glioblastoma. One of our [medulloblastoma] patients har-
bored 11 somatic mtDNA mutations.’’ Unfortunately, this
study [40] is another example of an artifactual result: leaving
aside a length polymorphism of a C-stretch (in HVS-II), the
following 11 mutations are recorded in Wong et al.’s patient
(their Table 1, case no. 124): C151T, C182T, G246A, A297G,
G317A, G7337A, G7521A, G7337A, T7389C, T15904C, and
A15937G. Three of these mutations have actually been shifted
by one position and should read G247A, G316A, and T15905C
instead. Then except for T15905C and A15937G these
mutations can be found in the African haplogroup L1c2
(Figure 1) [15,35], and compare with lineages no. 173 and no.
328 of Herrnstadt et al. [16,17]). It is then probably no
coincidence that the ‘‘novel germ-line variation’’ reported in
their Table 1b ([40], p. 3869) also testiﬁes to two mutations,
G10688A and T10810C (previously listed by Fliss et al. [3]),
that would be observed with all haplogroup L0 and L1
sequences. In a recent report from the same group [41],
patient HE19 was found to harbor 10 differences between
DNA in liver cancer and normal tissue. Six of them (A189G,
C194T, T195C, T199C, T204C, and G207A) in the tumor
tissue point to haplogroup W (see, for instance, USA.-
CAU.000453 in the SWGDAM database; Figure 1), whereas
three mutations, C456T, T489C, and (523–524)del, in the
normal tissue could point to the East Asian haplogroup D5b
(compare with THA.ASN.000058 in the SWGDAM database).
The study carried out by Liu et al. [42] on ovarian
carcinomas includes at least one instance suspicious of
sample mix-up or contamination. Namely, the normal tissue
of patient OV88 carries mutation A249del (with no
mutation at 489) characteristic of haplogroup F, whereas
the tumor mtDNA shows the mutations T146C, T199C,
T489C (characteristic of haplogroup M7c [43,44] plus T152C
(which has also been observed in M7c sequences from East
Asia; for example, in CHN.ASN.000337, JPN.ASN.000103,
and THA.ASN.000048 from the SWGDAM database). Since
this array of homoplasmic HVS-II mutations matches a
pathway in the Chinese mtDNA phylogeny, we are led to
conclude that the ovarian cancer mtDNA and the serum and
normal tissue mtDNA of OV88 likely came from two
different individuals. In their Table 1, many mutations
point to several East Asian haplogroups (see [18]), and thus
these mutations do not have anything to do with ovarian
carcinomas (see also Figure 1).
Chen et al. [45] aimed at tracing somatic mutations in 16
cases of prostate cancer, by sequencing the highly hyper-
variable mtDNA control region in subjects with prostate
cancer. Their Table 1 reports a patient (case 1) bearing eight
‘‘instabilities,’’ namely, mutations A16182C, A16183C,
T16189C, C16232A, T16249C, G16274A, T16304C, and
T16311C, leaving aside (522–523)del. Except for G16274A,
which seems to be a private mutation, this is unmistakably a
HVS-I haplotype belonging to haplogroup F1b, which is
frequently found in China [18,43,44]. Not accidentally, all
these variants were detected as heteroplasmies; therefore, this
represents a perfect instance of contamination from a
biological source carrying this F1b haplotype. Table 1 testiﬁes
to yet another highly suspicious example: case 4 carries nine
somatic near-homoplasmic mutations (besides a C-stretch
length polymorphism), among which A73G, G499A, A16182C,
A16183C, T16189C, and T16217C happen to constitute the
control-region mutations (relative to rCRS) of a genuine
member of the East Asian haplogroup B4b [18], except for
position 263, at which the vast majority of mtDNA sequences
agree anyway but differ from rCRS. Additional information
about case 4 is given in Chen et al. [46], where the B4bd
characteristic mutation G15535A is reported. Moreover,
among several serial tumor sections, one (C1) conﬁrms
haplogroup status B4b with G499A. On the other hand, the
mtDNA of section C2 is clearly a member of haplogroup K1a,
whereas the other sections would be compatible with
haplogroup HV status. Therefore, multiple sample mix-up
or contamination events are the most plausible cause under-
lying the seemingly close relationship among cases 1, 4, and 6,
which they have instead interpreted as follows: ‘‘The non-
random distribution of somatic mutations raises the possi-
bility that certain constellations of sequence variation might
be prone to somatic mutations’’([45], p. 6472). When Chen et
al. ([45], p. 6471) claimed that ‘‘the somatic mutations cannot
be explained by experimental error or by contamination of
nuclear mtDNA pseudogenes,’’ this may have been so, but
profuse sample mix-up or cross-contamination perfectly
explains the results.
The recent study of mtDNA control-region mutations in
patients with esophageal squamous cell carcinoma [47]
constitutes another good case for sample crossover. The
mtDNA of the normal esophageal tissue of case 21 bears
mutations C150T, C16067T, A16164G, A16171G, C16172T,
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A16182C, A16183C, T16362C, and T16519C and therefore
belongs to haplogroup D5a. Interestingly, the blood sample
shared all mutations with the normal esophageal tissue,
except for having heteroplasmies at positions 16067, 16164,
and 16171. In contrast, the tumor mtDNA contains C16184T,
T16298C, T16443C, G16470A, G16471A, G16473A, and
T16519C, which point to haplogroup M8a. Since only the
mutations were reported that distinguish tumor mtDNA from
blood mtDNA, we can expect that both actually share the
motif A73G, A263G, T489C, T16189C, and C16223T [18]. The
contrast between the two different sequences is well reﬂected
by the pair CHN.ASN.000113 and CHN.ASN.000270 in the
SWGDAM database. It then seems that one mutation in the
blood sample was overlooked (at position 16266) and one in
the tumor sample (at position 16319), but this cannot disturb
the clear-cut haplogroup allocations. Case 20 [47] testiﬁes to
yet another sample mix: here tumor and adjacent normal
tissue bear the same mtDNA variants (except for one
heteroplasmy at 16266) in HVS-I, namely, C16185T,
C16223T, C16260T, and T16298C, whereas the mtDNA
sequence from blood is reported to have C16256T,
C16270T, and A16399G. We are thus seeing here the clean
contrast between a haplogroup Z and a (West Eurasian)
haplogroup U5a1 sequence.
Discussion
Somatic mutations, in a heteroplasmic or a homoplasmic
state, can occur in all kinds of tissues and body ﬂuids of
patients affected by cancer or genetic diseases and in healthy
controls [4,48,49]. The problematic ﬁndings of Polyak et al. [2]
and Fliss et al. [3] have been uncritically accepted [50] and
cited in virtually every study of perceived mtDNA alterations
in tumors. There seems to be a general expectation that the
amount of somatic mutation can be elevated in tumors. The
problem then is that instances reported with a whole array of
seemingly somatic mutations would conﬁrm this expectation
and be taken at face value instead of as a hint at
contamination or sample mix-up. The main consequence of
such sequencing disasters is that most of these ﬂawed results
are not ﬁltered out from the clinical literature, thus adding
more noise to the interpretation of the role of mtDNA in the
complex tumor process. This eventually leads to a vicious
cycle of ill-based interpretations of mutational variation in
tumors.
We have detected innumerable deﬁciencies in the clinical
literature related to the analysis and interpretation of
mtDNA data in tumor samples. There is no precedent that
we know of in the genetics literature for such a high number
of ﬂawed papers (most of them published in high-rank
journals), which affect a whole subﬁeld of clinical research.
Since what we show here is based on the extremely meager
information generally available in these published reports, we
have every reason to believe that this is only the tip of the
iceberg. Note also that the database of coding-region variants
in natural populations is still limited (although currently
comprising more than 2,100 complete genomes), so some
more mistakes in this literature await detection. Moreover, we
must keep in mind that the phylogenetic approach used here
is certainly not able to detect all errors.
We have found that the vast majority (.80%) of the
studies dealing with potential functional implications of the
mtDNA molecule in tumorigenesis (and providing data for
inspection) are based on faulty data with surreal ﬁndings.
The present report should lead us to reconsider the role of
mtDNA in tumorigenesis. Probably we should abandon the
exciting ﬁndings unleashed as a result of the many
sequencing failures that accumulated during this last decade.
A model consisting of basically two main stages [6]—namely,
(i) accumulation of homoplasmic mutations in mtDNA-
unstable sites during tumorigenesis, and (ii) a consequential
effect on the cell physiology—is still valid in order to
explain the mtDNA changes occurring during the tumoral
process.
The clues to understanding the causes of pitfalls in mtDNA
sequencing are extensively discussed [7–12,14,17]. Degraded
DNA or extremely low quantities of DNA from old frozen
samples or inadequately stored samples (in parafﬁn, for
example) used in many clinical/oncogenetic studies would
explain the notoriously low quality of sequence results as well
as an elevated risk of contamination. For instance, one can
only obtain very small amounts of DNA using the laser-
capture microdissection technique employed by Chen et al.
([45]; see above) to retrieve cancerous and noncancerous
samples from serial tissue sections. Contamination and
sample degradation would greatly affect the quality of DNA
during the subsequent processes and ﬁnally contribute to rich
mtDNA heterogeneity in the sequence. In these situations of
limited quantities of endogenous DNA, the clinical geneticist
would do well to employ many of the checks for authenticity
proposed for ancient DNA studies [51]). In a way, the current
situation in the ﬁeld of carcinogenesis and mtDNA resembles
the state of the art of ancient DNA sequencing in those early
days where loads of contaminated samples were ampliﬁed
and claimed to yield ‘‘mummy mtDNA.’’
It is unfortunate that clinical studies in oncogenetics do
not routinely report comprehensive sequencing results. This
has two important consequences (see also [6]): ﬁrst, the
phylogenetic interpretation of the spectra of the mtDNA
variants found is limited, and second, the phylogenetic
proofreading of sequence data cannot be carried out
properly by referees and readers.
In short, we advise authors and editors of scientiﬁc journals
that (i) special care must be taken for sequencing and
documentation since conclusions fully depend on the
sequencing data; (ii) raw sequence data must be made fully
accessible to referees and readers in order to allow a critical
evaluation of the results [11,12] and proofreading during the
reviewing process. Although this sounds routine, it is striking
to observe that in the clinical literature related to tumori-
genesis, we have not seen cases—with a very few exceptions
(for example, [6])—that provide the complete primary
sequencing results; (iii) referring to the mutation lists in
MITOMAP is not sufﬁcient; in addition, the complete record
of the data from the population genetics ﬁeld should be
consulted as well.
The use of phylogenetic tools is highly recommended for
the medical ﬁeld, not only for the purpose of data analysis but
also in the design of appropriate mtDNA studies [52]. In this
way, the distinction between neutral polymorphisms in
human populations and the mutations associated with the
tumor process [6] or with other human disorders [53,54]
stands a chance of being realized.
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Patient Summary
Background DNA carries the genetic ‘‘blueprint’’ of all living things, and
everyone has slightly different DNA from everyone else. DNA is found in
the cell nucleus but also in other parts (organelles) of the cell called
mitochondria. Techniques have been developed to analyze the differ-
ences between the mitochondrial DNA (mtDNA) of different people.
Several scientific and medical uses are now being made of these tests,
and the results have been stored on international databases.
Why Was This Study Done? Many scientists believe that faults
(mutations) in mtDNA play a part in the development of cancer and
that tests that look for faulty mtDNA are a way of diagnosing cancer in its
very earliest stages. (This could be important because cancer treatment
is more effective if done early.) Other scientists claim that there have
been experimental errors in the study of mtDNA and cancer (for
example, samples may have been mixed up, or one sample may have
been contaminated with cells from another) and that faulty mtDNA is
not a sign of cancer. These authors wanted to investigate whether the
previously published studies were correct.
What Did the Researchers Do and Find? The authors of this paper
point out that, if the mtDNA from a cancer tumor and the mtDNA of
normal tissue from the same patient are shown by analysis to differ not
just a little, but considerably, then this cannot be the result of a fault
appearing in the tumor mtDNA. Instead it must mean that a mistake was
made in the laboratory by mixing up DNA from different human sources.
The researchers looked at international databases of mtDNA and the
mtDNA phylogeny (evolutionary reconstruction of the human mtDNA
lineages), and their conclusion was that most of the differences between
tumor mtDNA and normal mtDNA are the result of experimental error.
According to the authors, the experimental process routinely followed in
these studies favors this kind of error.
What Do These Finings Mean? The widely held view of scientists about
the role of mtDNA in the development of cancer appears to be wrong.
We do not know what role, if any, mtDNA plays.
Where Can I Get More Information Online? This is a very specialized
paper with no immediate implications for change in the way in which
cancer is treated. Here are some sources of general information on
cancer.
National Cancer Institute (US):
http://www.cancer.gov/
Cancer Research UK:
http://www.cancerresearchuk.org/aboutcancer/?version¼1/
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